All In Biotech

Drug Trial Radar · NCT05089708

AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation

Evaluation of Acne-induced Hyperpigmentation During Treatment of Acne Vulgaris Subjects With Trifarotene 50 μg/g Cream Versus Vehicle Cream Over 24 Weeks

Last checked: Nov 20, 2026Latest source record: Dec 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 123 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

123

Actual

Start

Dec 22, 2021

Primary completion

Dec 15, 2022

Study completion Dec 15, 2022

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Oct 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 13 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of Trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle cream in the treatment of moderate acne vulgaris with risk of acne-induced post inflammatory hyperpigmentation (PIH) after 24 weeks of treatment in facial acne participants

Conditions

  • Acne Vulgaris

Interventions

  • Trifarotene CreamDrug

    Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks

  • Trifarotene Vehicle CreamDrug

    Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change From Baseline in Post-Inflammatory Hyperpigmentation (PIH) Overall Disease Severity (ODS) Scores at Week 24Time frame: Baseline and Week 24

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • Galderma Investigational Site #8636

    Fountain Valley, California

  • Galderma Investigational Site #8224

    Fremont, California

  • Galderma Investigational Site #8358

    San Diego, California

  • Galderma Investigational Site #9955

    San Diego, California

  • Galderma Investigational Site #7012

    Lutz, Florida

  • Galderma Investigational Site #8184

    Maitland, Florida

  • Galderma Investigational Site #8764

    Tampa, Florida

  • Galderma Investigational Site #9950

    Evansville, Indiana

  • Galderma Investigational Site #9952

    Baton Rouge, Louisiana

  • Galderma Investigational Site #8606

    New Orleans, Louisiana

  • Galderma Investigational Site #8012

    Glenn Dale, Maryland

  • Galderma Investigational Site #9948

    Hyattsville, Maryland

  • Galderma Investigational Site #8554

    Detroit, Michigan

  • Galderma Investigational Site #8108

    Las Vegas, Nevada

  • Galderma Investigational Site #8620

    New York, New York

  • Galderma Investigational Site #9956

    New York, New York

  • Galderma Investigational Site #9949

    New York, New York

  • Galderma Investigational Site #9953

    Tulsa, Oklahoma

  • Galderma Investigational Site #8207

    Nashville, Tennessee

  • Galderma Investigational Site #9920

    Arlington, Texas

  • Galderma Investigational Site #8329

    San Antonio, Texas

  • Galderma Investigational Site #8433

    San Antonio, Texas

  • Galderma Investigational Site #6277

    Pontevedra, Spain

  • Galderma Investigational Site #6192

    Zaragoza, Aragon, Spain

  • Galderma Investigational Site #6278

    Manises, Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.